LMR Partners’s Aspire Biopharma ASBP Stock Holding History

LMR Partners’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-125	Closed	-$1.65M	–	1357
2024 Q1	$1.65M	Hold	125	–	–	0.02%	586
2023 Q4	$1.63M	Hold	125	–	–	0.02%	506
2023 Q3	$1.62M	Hold	125	–	–	0.02%	424
2023 Q2	$1.57M	Sell	125 -83	-40%	-$1.04M	0.02%	386
2023 Q1	$2.63M	Hold	208	–	–	0.04%	371
2022 Q4	$2.58M	Buy	+208	New	+$2.55M	0.04%	438

Other funds holding ASBP

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LMR Partners's ASBP Position: Q2 2024 in Review

LMR Partners sold out of Aspire Biopharma (ASBP) in Q2 2024, closing a stake of 125 shares — an estimated $1.65M sold.

LMR Partners first reported a position in ASBP in Q4 2022 and held it in 6 quarters. The position peaked at $2.63M in Q1 2023. 3 funds tracked by Wall St. Rank hold ASBP as of Q2 2024.

LMR Partners reported no remaining Aspire Biopharma position as of Q2 2024 after selling out during the quarter.
LMR Partners sold 125 Aspire Biopharma shares in Q2 2024, an estimated $1.65M.
LMR Partners first reported a position in Aspire Biopharma in Q4 2022 and held it in 6 quarters.
LMR Partners's Aspire Biopharma position peaked at $2.63M in Q1 2023.
3 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.